Oguchi disease

Oguchi disease. It is a rare, Autosomal recessive form of Congenital stationary night blindness characterized by a unique golden-yellow discoloration of the Retina that normalizes after prolonged dark adaptation, known as the Mizuo phenomenon. First described by Japanese ophthalmologist Chuta Oguchi in the early 20th century, the condition is non-progressive and primarily affects Rod cell function. While central Visual acuity is typically preserved, patients experience significant Nyctalopia from birth.

Signs and symptoms

The hallmark symptom is profound Night blindness present from infancy, though daytime vision remains largely intact. The pathognomonic clinical sign is the Mizuo phenomenon, where the ocular fundus exhibits an unusual metallic, golden-yellow sheen under light-adapted conditions. After several hours in complete darkness, this discoloration fades, and the Retina reverts to a more normal reddish appearance. Visual acuity and Visual field are usually normal, distinguishing it from progressive retinal degenerations like Retinitis pigmentosa. Some patients may report mild Photophobia or difficulties with Mesopic vision.

Genetics

The condition is inherited in an Autosomal recessive manner, requiring mutations in both alleles of the responsible gene. Two genes have been implicated, both encoding crucial proteins in the Phototransduction cascade within rod photoreceptors. Mutations in the SAG gene, which encodes Arrestin, are responsible for Oguchi disease type 1. Type 2 is caused by mutations in the GRK1 gene, which encodes Rhodopsin kinase. These genetic defects are most frequently identified in patients of Japanese descent, though cases have been reported in other populations including European, Indian, and Pakistani individuals.

Pathophysiology

The disease pathophysiology centers on a disruption in the Phototransduction cascade, specifically the deactivation phase of Rhodopsin. In healthy rods, light-activated Rhodopsin is phosphorylated by rhodopsin kinase and then bound by Arrestin to terminate the signal. Mutations in either GRK1 or arrestin prevent proper shut-off of the phototransduction cascade. This leads to constitutive activity, effectively "bleaching" the rod visual pigment even in the dark and causing the characteristic Night blindness. The abnormal accumulation of certain metabolites or altered light reflection from the Retinal pigment epithelium is thought to produce the striking Mizuo phenomenon.

Diagnosis

Diagnosis is based on clinical history, characteristic fundoscopic findings, and specialized electrophysiological testing. The Mizuo phenomenon is observed during Ophthalmoscopy. The cornerstone of functional diagnosis is the Electroretinogram, which shows a severely reduced or absent Scotopic rod response under dark-adapted conditions. After prolonged dark adaptation, the rod response may show some improvement, a key diagnostic feature. Optical coherence tomography may be used to assess retinal structure, which is typically normal, helping to differentiate it from Retinitis pigmentosa or Fundus albipunctatus.

Management

There is no cure or specific treatment to restore normal Rod cell function. Management is supportive and focuses on patient counseling and adaptive strategies. Genetic counseling is recommended for affected individuals and their families. Utilization of low-vision aids and ensuring adequate lighting for night-time activities can help manage Night blindness. Patients are advised to take precautions in low-light environments. The condition is non-progressive, and the prognosis for maintaining stable daytime visual acuity throughout life is excellent.

History

The disease was first described in 1907 by the Japanese ophthalmologist Chuta Oguchi, who published his observations on the unusual fundus appearance and associated Night blindness. The peculiar reversible discoloration of the retina was later termed the Mizuo phenomenon by another Japanese researcher, Gen-ichi Mizuo, in 1913. Early research was conducted primarily at the University of Tokyo. The genetic basis began to be elucidated in the 1990s, with the identification of mutations in the SAG gene by researchers including Toshimichi Shinohara and later in the GRK1 gene, linking the condition definitively to the Phototransduction pathway. Category:Congenital disorders of eye